Analyze Diet

Topic:Ciprofloxacin

Ciprofloxacin is a broad-spectrum antibiotic belonging to the fluoroquinolone class, commonly used in veterinary medicine, including equine practice. It functions by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes critical for bacterial DNA replication and transcription. In horses, ciprofloxacin is utilized to treat a variety of bacterial infections, particularly those caused by Gram-negative organisms. The pharmacokinetics, efficacy, and safety profile of ciprofloxacin in equine patients are subjects of ongoing research. This page compiles peer-reviewed research studies and scholarly articles that explore the pharmacological properties, therapeutic applications, and potential side effects of ciprofloxacin in horses.
Detection and genomic characterization of a multidrug-resistant Salmonella Newport co-harbouring blaCMY-2, qnrB19 and mcr-9 from the diarrheic faeces of a foal.
Journal of global antimicrobial resistance    October 5, 2023   Volume 35 198-201 doi: 10.1016/j.jgar.2023.09.019
Braga PRC, Dos Santos CA, Bertani AMJ, Vieira T, Amarante AF, Reis AD, Sacchi CT, Camargo CH, Ribeiro MG, Borges AS, Tiba-Casas MR.This study reports the genomic characterization of the multidrug resistant Salmonella Newport strain 195_20 recovered from the diarrheic faeces of a foal in Brazil and co-harbouring the mcr-9, blaCMY-2 and qnrB19 antibiotic resistance genes. Bacterial isolate positive for mobile colistin resistance gene (mcr-9) was submitted to antimicrobial susceptibility testing by disk diffusion and broth microdilution for colistin and polymyxin B. The isolate was submitted to whole genome sequencing by Illumina technology and Nanopore Sequencing. Conjugation assays, plasmid sizes determined by S1-PFGE and ...
Ciprofloxacin reduces tenocyte viability and proteoglycan synthesis in short-term explant cultures of equine tendon.
PeerJ    August 30, 2021   Volume 9 e12003 doi: 10.7717/peerj.12003
James S, Schuijers J, Daffy J, Cook J, Samiric T.Fluoroquinolones are an effective, broad-spectrum antibiotic used to treat an array of bacterial infections. However, they are associated with an increased risk of tendinopathy and tendon rupture even after discontinuation of treatment. This condition is known as fluoroquinolone-associated tendinopathy, the underlying mechanisms of which are poorly understood. While many factors may be involved in the pathophysiology of tendinopathies in general, changes in tenocyte metabolism and viability, as well as alteration of proteoglycan metabolism are prominent findings in the scientific literature. T...
Fluoroquinolone exposure in utero did not affect articular cartilage of resulting foals.
Equine veterinary journal    July 20, 2020   Volume 53, Issue 2 385-396 doi: 10.1111/evj.13295
Ellerbrock RE, Canisso IF, Larsen RJ, Garrett KS, Stewart MC, Herzog KK, Kersh ME, Moshage SG, Podico G, Lima FS, Childs BA.Recent studies have shown that fluoroquinolones, specifically, enrofloxacin and its active metabolite (ciprofloxacin), cross the equine placenta without causing gross or histological lesions in the first and third trimester fetuses or resulting foal. However, it is possible that in utero exposure to fluoroquinolones may cause subtle lesions not detectable by standard means; thus, a more in-depth assessment of potential toxicity is warranted. Objective: To use quantitative magnetic resonance imaging (qMRI), biomechanical testing, and chondrocyte gene expression to evaluate the limbs of foals ex...
Tear, cornea, and aqueous humor concentrations of ciprofloxacin and moxifloxacin after topical ocular application in ophthalmologically normal horses.
American journal of veterinary research    March 2, 2011   Volume 72, Issue 3 398-403 doi: 10.2460/ajvr.72.3.398
Westermeyer HD, Hendrix DV, Ward DA, Cox SK.To determine ocular tissue drug concentrations after topical ocular administration of 0.3% ciprofloxacin and 0.5% moxifloxacin in ophthalmologically normal horses. Methods: 24 ophthalmologically normal adult horses. Methods: 0.3% ciprofloxacin and 0.5% moxifloxacin solutions (0.1 mL) were applied to the ventral conjunctival fornix of 1 eye in each horse as follows: group 1 (n = 8) at 0, 2, 4, and 6 hours; group 2 (8) at 0, 2, 4, 6, and 10 hours; and group 3 (8) at 0, 2, 4, 6, 10, and 14 hours. Tears, cornea, and aqueous humor (AH) were collected at 8, 14, and 18 hours for groups 1, 2, and 3, r...
Pharmacokinetics of topically applied ciprofloxacin in equine tears.
Veterinary ophthalmology    November 1, 2007   Volume 10, Issue 6 344-347 doi: 10.1111/j.1463-5224.2007.00566.x
Hendrix DV, Stuffle JL, Cox SK.To evaluate the pharmacokinetics of topically applied ciprofloxacin 0.3% ophthalmic solution in tears of healthy horses. Methods: Twenty healthy, adult, mixed-breed horses. Methods: Twenty study horses were confirmed free of ophthalmic disease by complete ophthalmic examination. Seventy microliters of 0.3% ciprofloxacin (Ciloxan) was placed in the ventral cul-de-sac of each eye using a microliter syringe and 19-g cannula. Population kinetics were carried out by sampling the tear film from the lower cul-de-sac of each eye with tear test strips at 5, 10, 15 and 30 min and 1, 2, 4 and 6 h post ad...
Detection of enrofloxacin and its metabolite ciprofloxacin in equine hair.
Research in veterinary science    June 16, 2004   Volume 77, Issue 2 143-151 doi: 10.1016/j.rvsc.2004.03.004
Dunnett M, Richardson DW, Lees P.Hair analysis to detect drug administration has not been studied extensively in horses. This study aimed to (a) develop an analytical method for enrofloxacin and its metabolite ciprofloxacin in mane and tail hair, (b) relate measured values to doses, routes of administration, hair colour, and (c) demonstrate long-term detectability. Samples were extracted in trifluoroacetic acid at 70 degrees C. Extracts were cleaned-up by solid-phase extraction and analysed by high-performance liquid chromatography with UV-diode array detection. Analyte recoveries were > 87%. Horses were sampled after therape...
Pharmacokinetics and endometrial tissue concentrations of enrofloxacin and the metabolite ciprofloxacin after i.v. administration of enrofloxacin to mares.
Journal of veterinary pharmacology and therapeutics    November 9, 2002   Volume 25, Issue 5 343-350 doi: 10.1046/j.1365-2885.2002.00434.x
Papich MG, Van Camp SD, Cole JA, Whitacre MD.Enrofloxacin was administered i.v. to five adult mares at a dose of 5 mg/kg. After administration, blood and endometrial biopsy samples were collected at regular intervals for 24 h. The plasma and tissue samples were analyzed for enrofloxacin and the metabolite ciprofloxacin by high-pressure liquid chromatography. In plasma, enrofloxacin had a terminal half-life (t(1/2)), volume of distribution (area method), and systemic clearance of 6.7 +/- 2.9 h, 1.9 +/- 0.4 L/kg, and 3.7 +/- 1.4 mL/kg/min, respectively. Ciprofloxacin had a maximum plasma concentration (Cmax) of 0.28 +/- 0.09 microg/mL. In ...
Effects of enrofloxacin and ciprofloxacin hydrochloride on canine and equine chondrocytes in culture.
American journal of veterinary research    May 9, 2001   Volume 62, Issue 5 704-708 doi: 10.2460/ajvr.2001.62.704
Egerbacher M, Edinger J, Tschulenk W.To study chondrotoxic effects of enrofloxacin (ENR) and ciprofloxacin hydrochloride (CFX) on canine and equine articular chondrocytes in culture and to compare the effects with that of cultivation in Mg2+-free medium. Methods: Chondrocytes from articular cartilage of 4- and 6 -month old dogs and 2- to 4- year-old horses. Methods: Chondrocytes were cultivated with 10, 40, 80, and 160 microg of CFX/ml, 10, 50, 100, and 150 microg of ENR/ml, or in Mg2+-free medium. A live-to-dead test was performed to test cytotoxic effects. Morphologic changes were evaluated by electron microscopy. An attachment...
Pharmacokinetics of ciprofloxacin in ponies.
Journal of veterinary pharmacology and therapeutics    February 1, 1995   Volume 18, Issue 1 7-12 doi: 10.1111/j.1365-2885.1995.tb00543.x
Dowling PM, Wilson RC, Tyler JW, Duran SH.The pharmacokinetics of ciprofloxacin was investigated in healthy, mature ponies. Ciprofloxacin was administered intravenously to six ponies at a dose of 5 mg per kg body weight. Seven days later, ciprofloxacin was administered orally to each pony at the same dose. Intravenous ciprofloxacin concentration vs. time data best fit a two-compartment open model with first-order elimination from the central compartment. Mean plasma half-life, based on the terminal phase, was 157.89 min (harmonic mean). Total body clearance of ciprofloxacin was 18.12 +/- 3.99 mL/min/kg. Volume of distribution at stead...